Literature DB >> 12206924

Changing trends in pregnancy outcome among HIV-infected women between 1985 and 1997 in two southern French university hospitals.

A Bongain1, A Berrebi, E Mariné-Barjoan, B Dunais, M Thene, C Pradier, J Y Gillet.   

Abstract

OBJECTIVES: To analyze risk factors for pregnancy outcome among HIV-infected women before and after introduction of AZT prophylaxis in 1994. STUDY
DESIGN: A prospective, two-center observational study conducted from 1 January 1985 to 31 December 1997. PATIENTS: Pregnant HIV-infected women followed in one of the obstetrics units during the study period. MAIN OUTCOME MEASURES: pregnancy outcome (normal delivery, ectopic pregnancy, spontaneous abortion, voluntary termination of pregnancy (TOP) according to year of pregnancy, age at pregnancy professional status, marital status, ethnic origin, mode of contamination, stage of disease, partner's human immunodeficiency virus (HIV) status and prior pregnancy.
RESULTS: One thousand one hundred and three pregnancies among 937 HIV-infected women were studied. Mean age of patients was 28.1 +/- 4.9 years. Pregnancy outcomes were distributed as follows: 473 normal deliveries, 589 TOP, 9 ectopic pregnancies and 32 spontaneous abortions. The proportion of TOP decreased from 59.4% before 1994 to 37.5% from 1994 (P < 0.001). In univariate analysis, mode of transmission, marital status, ethnic origin, partner's HIV status and prior pregnancy were also significantly correlated with pregnancy outcome. However, after adjustment by logistic regression for each period (before and after 1994), mode of transmission no longer appeared to influence pregnancy outcome.
CONCLUSION: Effective prevention of mother-to-child transmission of HIV infection appears to have influenced HIV-infected women's decisions on continuing their pregnancy to term. Incidence of voluntary TOP has decreased significantly after introduction of AZT. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12206924     DOI: 10.1016/s0301-2115(02)00103-3

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

Review 1.  Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.

Authors:  Vitaly A Kushnir; William Lewis
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

2.  Contemplating abortion: HIV-positive women's decision to terminate pregnancy.

Authors:  Sarah Maccarthy; Jennifer J K Rasanathan; Ann Crawford-Roberts; Ines Dourado; Sofia Gruskin
Journal:  Cult Health Sex       Date:  2014-01-06

Review 3.  HIV protease inhibitors in pregnancy : pharmacology and clinical use.

Authors:  Nisha Andany; Mona R Loutfy
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

4.  Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy.

Authors:  Anjali Sharma; Joseph G Feldman; Elizabeth T Golub; Julie Schmidt; Sylvia Silver; Esther Robison; Howard Minkoff
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

5.  Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS).

Authors:  Anna Hachfeld; Andrew Atkinson; Alexandra Calmy; Begoña Martinez de Tejada; Barbara Hasse; Paolo Paioni; Christian R Kahlert; Noémie Boillat-Blanco; Marcel Stoeckle; Karoline Aebi-Popp
Journal:  HIV Med       Date:  2021-09-02       Impact factor: 3.094

6.  Lifetime induced abortion: a comparison between women living and not living with HIV.

Authors:  Flávia Bulegon Pilecco; Luciana Barcellos Teixeira; Alvaro Vigo; Michael E Dewey; Daniela Riva Knauth
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

7.  Bolstering the Evidence Base for Integrating Abortion and HIV Care: A Literature Review.

Authors:  Ruth Manski; Amanda Dennis; Kelly Blanchard; Naomi Lince; Dan Grossman
Journal:  AIDS Res Treat       Date:  2012-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.